Acute promyelocytic leukaemia: novel insights into the mechanisms of cure

Key Points Promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα) is a gain-of-function protein that represses RARα and non-RARα target genes and disrupts PML nuclear bodies. This results in immortal proliferation and the inhibition of terminal differentiation. Various clinical regimens combi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Cancer 2010-11, Vol.10 (11), p.775-783
Hauptverfasser: de Thé, Hugues, Chen, Zhu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 783
container_issue 11
container_start_page 775
container_title Nature reviews. Cancer
container_volume 10
creator de Thé, Hugues
Chen, Zhu
description Key Points Promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα) is a gain-of-function protein that represses RARα and non-RARα target genes and disrupts PML nuclear bodies. This results in immortal proliferation and the inhibition of terminal differentiation. Various clinical regimens combining retinoic acid (RA), arsenic trioxide and anthracyclines now definitively cure up to 90% of patients with acute promyelocytic leukaemia (APL). RA induces APL differentiation and transient remissions. Arsenic trioxide triggers both apoptosis and differentiation and, as a single agent, allows many APL cures. As initially shown in mouse models, their combination definitively cures most patients. Mechanistically, therapy-induced transcriptional activation (or derepression) is responsible for APL cell differentiation, and PML–RARα degradation by RA or arsenic trioxide results in APL eradication. Arsenic trioxide targets PML through oxidation-triggered disulphide bond formation and direct binding. This results in PML and PML–RARα sumoylation, ubiquitylation and proteasome-mediated degradation. Therapy-triggered oncoprotein degradation could be a generally applicable strategy to treat malignancies driven by fusion proteins or overactivation of transcription factors. This Review discusses the new data that have revealed surprising insights into the pathogenesis of acute promyelocytic leukaemia (APL) and the mechanism by which retinoic acid plus arsenic trioxide combination therapy targets the oncogenic fusion protein promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα), curing most cases of APL. The fusion oncogene, promyelocytic leukaemia ( PML )–retinoic acid receptor-α ( RARA ), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML–RARα for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.
doi_str_mv 10.1038/nrc2943
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_864953435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A241278607</galeid><sourcerecordid>A241278607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-760bc870b0655510fdf54d46aadad07f529308f3941a0c159b237b2c5de67d5b3</originalsourceid><addsrcrecordid>eNqFkl1rFDEUhgex2A_FX6AMFrQ3W_OdiXdLUVsoeKPg3ZDJnNlJzSRtkhH235tlt6vVguQih5znvJw351TVS4zOMaLNex8NUYw-qY4wk2yBpWie7mP-_bA6TukGISywxM-qQ4KUEIqQo-pqaeYM9W0M0xpcMOtsTe1g_qFhsvpD7cNPcLX1ya7GnEqQQ51HqCcwo_Y2TakOQ23mCM-rg0G7BC9290n17dPHrxeXi-svn68ultcLwxTJCylQZxqJOiQ45xgN_cBZz4TWve6RHDhRFDUDVQxrZDBXHaGyI4b3IGTPO3pSvdvqlp7vZki5nWwy4Jz2EObUNoIpThnl_yUlV41sFMWFfPMXeRPm6IuNDSSo5IQW6HQLrbSD1voh5KjNRrJdEoaJbASShTp_hCqnLx9qgofBlvcHBW__KBhBuzym4OZsg08PwZ0dE0NKEYb2NtpJx3WLUbvZgna3BYV8vbMzdxP0e-5-7AU42wKppPwK4m-__2q92qJe5zLlvdZ9_hfICMEj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>759637523</pqid></control><display><type>article</type><title>Acute promyelocytic leukaemia: novel insights into the mechanisms of cure</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>de Thé, Hugues ; Chen, Zhu</creator><creatorcontrib>de Thé, Hugues ; Chen, Zhu</creatorcontrib><description>Key Points Promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα) is a gain-of-function protein that represses RARα and non-RARα target genes and disrupts PML nuclear bodies. This results in immortal proliferation and the inhibition of terminal differentiation. Various clinical regimens combining retinoic acid (RA), arsenic trioxide and anthracyclines now definitively cure up to 90% of patients with acute promyelocytic leukaemia (APL). RA induces APL differentiation and transient remissions. Arsenic trioxide triggers both apoptosis and differentiation and, as a single agent, allows many APL cures. As initially shown in mouse models, their combination definitively cures most patients. Mechanistically, therapy-induced transcriptional activation (or derepression) is responsible for APL cell differentiation, and PML–RARα degradation by RA or arsenic trioxide results in APL eradication. Arsenic trioxide targets PML through oxidation-triggered disulphide bond formation and direct binding. This results in PML and PML–RARα sumoylation, ubiquitylation and proteasome-mediated degradation. Therapy-triggered oncoprotein degradation could be a generally applicable strategy to treat malignancies driven by fusion proteins or overactivation of transcription factors. This Review discusses the new data that have revealed surprising insights into the pathogenesis of acute promyelocytic leukaemia (APL) and the mechanism by which retinoic acid plus arsenic trioxide combination therapy targets the oncogenic fusion protein promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα), curing most cases of APL. The fusion oncogene, promyelocytic leukaemia ( PML )–retinoic acid receptor-α ( RARA ), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML–RARα for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.</description><identifier>ISSN: 1474-175X</identifier><identifier>EISSN: 1474-1768</identifier><identifier>DOI: 10.1038/nrc2943</identifier><identifier>PMID: 20966922</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1059/602 ; 631/92/436/2388 ; 692/699/67/1990/283/1897 ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; Cell Differentiation ; Cellular signal transduction ; Chemotherapy ; Health aspects ; Humans ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukemia, Promyelocytic, Acute - pathology ; Models, Biological ; review-article</subject><ispartof>Nature reviews. Cancer, 2010-11, Vol.10 (11), p.775-783</ispartof><rights>Springer Nature Limited 2010</rights><rights>COPYRIGHT 2010 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Nov 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-760bc870b0655510fdf54d46aadad07f529308f3941a0c159b237b2c5de67d5b3</citedby><cites>FETCH-LOGICAL-c492t-760bc870b0655510fdf54d46aadad07f529308f3941a0c159b237b2c5de67d5b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20966922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Thé, Hugues</creatorcontrib><creatorcontrib>Chen, Zhu</creatorcontrib><title>Acute promyelocytic leukaemia: novel insights into the mechanisms of cure</title><title>Nature reviews. Cancer</title><addtitle>Nat Rev Cancer</addtitle><addtitle>Nat Rev Cancer</addtitle><description>Key Points Promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα) is a gain-of-function protein that represses RARα and non-RARα target genes and disrupts PML nuclear bodies. This results in immortal proliferation and the inhibition of terminal differentiation. Various clinical regimens combining retinoic acid (RA), arsenic trioxide and anthracyclines now definitively cure up to 90% of patients with acute promyelocytic leukaemia (APL). RA induces APL differentiation and transient remissions. Arsenic trioxide triggers both apoptosis and differentiation and, as a single agent, allows many APL cures. As initially shown in mouse models, their combination definitively cures most patients. Mechanistically, therapy-induced transcriptional activation (or derepression) is responsible for APL cell differentiation, and PML–RARα degradation by RA or arsenic trioxide results in APL eradication. Arsenic trioxide targets PML through oxidation-triggered disulphide bond formation and direct binding. This results in PML and PML–RARα sumoylation, ubiquitylation and proteasome-mediated degradation. Therapy-triggered oncoprotein degradation could be a generally applicable strategy to treat malignancies driven by fusion proteins or overactivation of transcription factors. This Review discusses the new data that have revealed surprising insights into the pathogenesis of acute promyelocytic leukaemia (APL) and the mechanism by which retinoic acid plus arsenic trioxide combination therapy targets the oncogenic fusion protein promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα), curing most cases of APL. The fusion oncogene, promyelocytic leukaemia ( PML )–retinoic acid receptor-α ( RARA ), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML–RARα for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.</description><subject>631/67/1059/602</subject><subject>631/92/436/2388</subject><subject>692/699/67/1990/283/1897</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cell Differentiation</subject><subject>Cellular signal transduction</subject><subject>Chemotherapy</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukemia, Promyelocytic, Acute - pathology</subject><subject>Models, Biological</subject><subject>review-article</subject><issn>1474-175X</issn><issn>1474-1768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkl1rFDEUhgex2A_FX6AMFrQ3W_OdiXdLUVsoeKPg3ZDJnNlJzSRtkhH235tlt6vVguQih5znvJw351TVS4zOMaLNex8NUYw-qY4wk2yBpWie7mP-_bA6TukGISywxM-qQ4KUEIqQo-pqaeYM9W0M0xpcMOtsTe1g_qFhsvpD7cNPcLX1ya7GnEqQQ51HqCcwo_Y2TakOQ23mCM-rg0G7BC9290n17dPHrxeXi-svn68ultcLwxTJCylQZxqJOiQ45xgN_cBZz4TWve6RHDhRFDUDVQxrZDBXHaGyI4b3IGTPO3pSvdvqlp7vZki5nWwy4Jz2EObUNoIpThnl_yUlV41sFMWFfPMXeRPm6IuNDSSo5IQW6HQLrbSD1voh5KjNRrJdEoaJbASShTp_hCqnLx9qgofBlvcHBW__KBhBuzym4OZsg08PwZ0dE0NKEYb2NtpJx3WLUbvZgna3BYV8vbMzdxP0e-5-7AU42wKppPwK4m-__2q92qJe5zLlvdZ9_hfICMEj</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>de Thé, Hugues</creator><creator>Chen, Zhu</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20101101</creationdate><title>Acute promyelocytic leukaemia: novel insights into the mechanisms of cure</title><author>de Thé, Hugues ; Chen, Zhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-760bc870b0655510fdf54d46aadad07f529308f3941a0c159b237b2c5de67d5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>631/67/1059/602</topic><topic>631/92/436/2388</topic><topic>692/699/67/1990/283/1897</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cell Differentiation</topic><topic>Cellular signal transduction</topic><topic>Chemotherapy</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukemia, Promyelocytic, Acute - pathology</topic><topic>Models, Biological</topic><topic>review-article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Thé, Hugues</creatorcontrib><creatorcontrib>Chen, Zhu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Thé, Hugues</au><au>Chen, Zhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute promyelocytic leukaemia: novel insights into the mechanisms of cure</atitle><jtitle>Nature reviews. Cancer</jtitle><stitle>Nat Rev Cancer</stitle><addtitle>Nat Rev Cancer</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>10</volume><issue>11</issue><spage>775</spage><epage>783</epage><pages>775-783</pages><issn>1474-175X</issn><eissn>1474-1768</eissn><abstract>Key Points Promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα) is a gain-of-function protein that represses RARα and non-RARα target genes and disrupts PML nuclear bodies. This results in immortal proliferation and the inhibition of terminal differentiation. Various clinical regimens combining retinoic acid (RA), arsenic trioxide and anthracyclines now definitively cure up to 90% of patients with acute promyelocytic leukaemia (APL). RA induces APL differentiation and transient remissions. Arsenic trioxide triggers both apoptosis and differentiation and, as a single agent, allows many APL cures. As initially shown in mouse models, their combination definitively cures most patients. Mechanistically, therapy-induced transcriptional activation (or derepression) is responsible for APL cell differentiation, and PML–RARα degradation by RA or arsenic trioxide results in APL eradication. Arsenic trioxide targets PML through oxidation-triggered disulphide bond formation and direct binding. This results in PML and PML–RARα sumoylation, ubiquitylation and proteasome-mediated degradation. Therapy-triggered oncoprotein degradation could be a generally applicable strategy to treat malignancies driven by fusion proteins or overactivation of transcription factors. This Review discusses the new data that have revealed surprising insights into the pathogenesis of acute promyelocytic leukaemia (APL) and the mechanism by which retinoic acid plus arsenic trioxide combination therapy targets the oncogenic fusion protein promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARα), curing most cases of APL. The fusion oncogene, promyelocytic leukaemia ( PML )–retinoic acid receptor-α ( RARA ), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML–RARα for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>20966922</pmid><doi>10.1038/nrc2943</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1474-175X
ispartof Nature reviews. Cancer, 2010-11, Vol.10 (11), p.775-783
issn 1474-175X
1474-1768
language eng
recordid cdi_proquest_miscellaneous_864953435
source MEDLINE; Nature; Alma/SFX Local Collection
subjects 631/67/1059/602
631/92/436/2388
692/699/67/1990/283/1897
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cell Differentiation
Cellular signal transduction
Chemotherapy
Health aspects
Humans
Leukemia, Promyelocytic, Acute - drug therapy
Leukemia, Promyelocytic, Acute - pathology
Models, Biological
review-article
title Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T02%3A18%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20promyelocytic%20leukaemia:%20novel%20insights%20into%20the%20mechanisms%20of%20cure&rft.jtitle=Nature%20reviews.%20Cancer&rft.au=de%20Th%C3%A9,%20Hugues&rft.date=2010-11-01&rft.volume=10&rft.issue=11&rft.spage=775&rft.epage=783&rft.pages=775-783&rft.issn=1474-175X&rft.eissn=1474-1768&rft_id=info:doi/10.1038/nrc2943&rft_dat=%3Cgale_proqu%3EA241278607%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=759637523&rft_id=info:pmid/20966922&rft_galeid=A241278607&rfr_iscdi=true